|
Male [n(%)]
|
16 (48.5)
|
22 (66.7)
|
x2 = 2.233
|
0.135
|
|
Age [(Mean ± SD), years]
|
62.3 ± 11.1
|
59.5 ± 12.5
|
t = 0.990
|
0.326
|
|
Hypertension [n(%)]
|
21 (63.6)
|
19 (57.6)
|
x2 = 0.254
|
0.614
|
|
Smoking [n(%)]
|
5 (15.2)
|
11 (33.3)
|
x2 = 2.970
|
0.085
|
|
Positive family history [n(%)]
|
7 (21.2)
|
7 (21.2)
|
–
|
1.000
|
|
BMI [(Mean ± SD), Kg/M2]
|
25.0 ± 4.4
|
25.2 ± 3.4
|
t = − 0.176
|
0.861
|
|
Diabetes history [(Mean ± SD), mouth]
|
9.0 (2~15.5)
|
5.0 (1.0~10.0)
|
z = −1.649
|
0.099
|
|
hs-CRP [M(Q1~Q3), mmol/l]
|
2.1 (0.5~6.6)
|
1.8 (0.5~6.7)
|
z = −0.250
|
0.802
|
|
Medications [n(%)]
|
|
Insulin
|
11.0 (33.3)
|
10.0 (30.3)
|
x2 = 0.070
|
0.792
|
|
Metformin
|
17.0 (51.5)
|
15.0 (45.5)
|
x2 = 0.243
|
0.622
|
|
α-glucosidase inhibitor
|
12.0 (36.4)
|
17.0 (51.5)
|
x2 = 1.538
|
0.215
|
|
Sulfonylureas
|
2.0 (6.1)
|
7.0 (21.2)
|
–
|
0.149
|
|
Glinide
|
1.0 (3.0)
|
4.0 (12.1)
|
–
|
0.355
|
|
DPP-4 inhibitor
|
0 (0.0)
|
1 (3.0)
|
–
|
1.000
|
|
Glucose control data
|
|
FPG [M(Q1~Q3), mmol/l]
|
8.6 (6.8~12.9)
|
8.8 (7.5~11.1)
|
z = − 0.023
|
0.982
|
|
2h PBG [M(Q1~Q3), mmol/l]
|
12.8 (10.6~18.1)
|
17.0 (15.2~20.8)
|
z = − 1.858
|
0.063
|
|
DGA [M(Q1~Q3), mmol/l]
|
11.0 (9.0~15.0)
|
11.9 (10.1~13.7)
|
z = − 0.301
|
0.763
|
|
HbAlc [M(Q1~Q3), %]
|
9.2 (8.2~10.5)
|
8.2 (8.2~9.4)
|
z = − 1.320
|
0.187
|
|
GA [M(Q1~Q3), %]
|
23.3 (19.3~27.2)
|
25.8 (20.0~36.3)
|
z = − 1.247
|
0.212
|
|
Glucose fluctuations of Short-term
|
|
SDBG [M(Q1~Q3), mmol/l]
|
2.1 (1.6~2.5)
|
2.9 (2.0~3.3)
|
z = − 2.520
|
0.012
|
|
PPGE [M(Q1~Q3), mmol/l]
|
2.8 (1.8~3.1)
|
2.2 (1.9~3.8)
|
z = − 0.917
|
0.359
|
|
LAGE [M(Q1~Q3), mmol/l]
|
5.9 (4.3~7.4)
|
7.5 (5.4~8.9)
|
z = − 2.123
|
0.034
|
|
SDBG < 2.0 mmol/l [n(%)]
|
15.0 (45.5)
|
9.0 (27.3)
|
x2 = 2.357
|
0.125
|
|
PPGE < 2.2 mmol/l [n(%)]
|
15.0 (45.5)
|
11.0 (33.3)
|
x2 = 1.015
|
0.314
|
|
LAGE< 4.4 mmol/l [n(%)]
|
9.0 (27.3)
|
4.0 (12.1)
|
x2 = 2.395
|
0.122
|
